Skip to content
Tenfell
Awarded contract
Published 21 Mar 2019

NHS England - Midlands and East Branded Medicines - Tranche B

NHS England · London

Key facts

Awarded
17 Jan 2019
Contract starts
01 Mar 2019
Contract ends
28 Mar 2021
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 27 suppliers

SupplierValue
Janssen-Cilag Ltd—
Pfizer Ltd—
Teva UK Ltd—
Bayer plc—
Amgen Ltd—
Sandoz Ltd—
Eli Lilly & Company Ltd—
Gedeon Richter UK Ltd—
Gilead Sciences Limited—
Ipsen—
Novartis Pharmaceuticals UK Ltd—
UCB Pharma Ltd—
Ferring Pharmaceuticals Limited—
LEO Pharma Ltd—
Bristol-Myers Squibb Pharmaceuticals Ltd—
Chiesi Limited—
ROVI Biotech Ltd—
Biogen Idec Ltd.—
Techdow Pharma England Ltd—
Astellas Pharma Ltd—
Aventis Pharma Ltd—
Daiichi Sankyo UK Ltd—
Genzyme Therapeutics Ltd—
Bedfont Cross | Stanwell Road | Feltham | Middlesex | TW14 8NX |—
Generics [UK] ta Mylan—
Originalis B.V.—
Pharmasure Limited Lentcroft, 10 Cassiobury Park Avenue, Watford—

Description

NHS Framework for the Midlands and East, Branded Medicines - Tranche B, Offer reference number: CM/PHR/16/5524

Period of framework agreement:

CM/PHR/16/5524/01 - NHS Framework for the Midlands and East, Branded Medicines - Tranche B - 1 March 2019 to 28 Feb 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/16/5524/02 - NHS Framework for the Midlands and East, Branded Medicines - Tranche B (Cytokine modulators and other monoclonal antibodies) - 1 March 2019 to 29 Feb 2020 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.